

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Joshi, et al.

SERIAL NO.: 10/056,913 GROUP ART UNIT: 1614

FILED: January 25, 2002 EXAMINER: Jones, D.

FOR: DELIVERY SYSTEMS AND METHODS FOR NOSCAPINE AND
NOSCAPINE DERIVATIVES, USEFUL AS ANTICANCER AGENTS




04/16/2003 HGUTEMA1 00000066 10056913

01 FC:2814 55.00 OP

Assistant Commissioner for
Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this document, together with any document referred to as enclosed or attached, is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 10th day of April, 2003.


Emily Guida

ATTORNEY DOCKET NO.: EMU144CIP
E2690/268902
DATE: April 10, 2003

TERMINAL DISCLAIMER

EMORY UNIVERSITY (hereinafter "the Assignee"), having an office at 1380 South Oxford Road, Atlanta, Georgia 30322, is the assignee of the entire right and interest of the above-identified application by virtue of and as evidenced by an Assignment recorded in the U.S. Patent and Trademark Office commencing at Reel 012883, Frame 0678.

The Assignee hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term (as presently shortened by any terminal disclaimer) of U.S. Patent No. 6,376,516 (hereinafter "Prior Patent"). The Assignee hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the

Amendment and Response
U.S. Serial No. 10/569,913

legal title to the Prior Patent shall be the same as the legal title to any patent issuing from the above-identified application, this agreement to run with any patent granted on the above-identified application and to be binding on the grantee, its successors or assigns.

The Assignee does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term (as presently shortened by any terminal disclaimer) of the Prior Patent in the event that it expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term (as presently shortened by any terminal disclaimer), except for the separation of legal title stated above.

Enclosed is a check in the amount of \$55.00, the small entity fee for filing this Terminal Disclaimer pursuant to 37 CFR § 1.20(d). Please charge any additional fees or credit any overpayment to Deposit Order Account No. 11-0855.

Respectfully submitted,



Kristin D. Mallatt
Attorney for Assignee
Reg. No. 46,895

OF COUNSEL:

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia, 30309-4530
404.815.6147

